ArticleJournal of translational medicine2016

Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma.

C De Divitiis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.